SU-250
SU-400
TA-300
Test mix 325
TE-300
TE-250
TC-200
TP-100
DECA-300 (ND-300)
TRENMIX-200
DP-100
MAST-200
TrX-100
PRIMO-100
PROVI-100
Blend-500
Blend-375

 

Bodybuilding estrogen's function

• Structural changes (promotion of the growth and development of female secondary sexual characteristics)
• Protein synthesis (increases hepatic production of binding proteins)
• Metabolism (accelerates body's metabolism, burns fat)
• Lipid profile (increases HDL, triglyceride; decreases LDL, fat deposition)
• Fluid balance (salt/sodium, water retention)
• Hormonal (increases growth hoe; increases cortisol, SHBG)

Product Name: Liraglutide 
Brand Name:Saxenda
CAS No.: 204656-20-2
Molecular Formula:C172H265N43O51
Molecular Weight: 3751.202g/mol
Purity : 99% HPLC
Appearance:  White Powder
Typical use:  Novel Anti-Obesity drug
Standard Packing :1mg,1g,10g
Shelf Life :2 years
Storage:Refrigeration away from light

Typical Application:
*Accelerated Muscle Growth
*Accelerated Fat Loss(Great for Cutting)
*Added Bone Mineral Density
*Potential for Male Birth Control
*No "Night Vision" Side Effects (Like S4)
*Faster Recovery Time Post-Workout

Victoza is FDA-approved for type 2 diabetes mellitus (DM) and prophylaxis for disorder of cardiovascular system as a result of type 2 diabetes. Its dosing involves titration to reduce gastrointestinal symptoms, such as nausea, diarrhea, and vomiting: initiate 0.6 mg daily subcutaneous injection for 1 week; increase to maintenance dose of 1.2 mg daily; and increase to 1.8 mg daily, as needed.
Liraglutide is also FDA-approved as Saxenda for obesity with a body mass index of 30kg/m2< or 27kg/m2 with the presence of at least 1 weight-related comorbid condition. Saxenda is initiated at 0.6 mg subcutaneous daily injection for 1 week, with weekly increments of 0.6 mg per day, until the maintenance dosage of 3 mg once daily is reached.3 If the patient misses a dose of liraglutide injection for more than 3 days, re-initiation at 0.6 mg is recommended to mitigate gastrointestinal (GI) symptoms.



Function

Other Products:

 ACP-105, a novel non-steroidal SARs. It is shown to be as potent and efficacious as test in in vitro assays without interaction at other hormone receptors. Moreover, ACP-105 demonstrates potent anabolic effects on muscle and bone with minimal effect on prostrate in preclinical models. ACP-105 is often a non-steroidal and selective androgen receptor agonist. ACP-105 belongs to a class of molecules called  (SARs). SARs may advance the standard of answer to a variety of disorders including muscle-wasting conditions and osteoporosis, with fewer unwanted effects as compared with current treatments based on test replacement.

 Typical Application:
*Increases in strength
* Fat Loss
* Low to No Virilization
* Endurance & Conditioning
*Nutrient Efficiency


 

 ACP-105 is a drug which acts as a potent, orally acti hormonesecretagogue, mimicking the stimulating action of the endogenous hormone ghrelin. It has been demonstrated to increase the release of, and produces sustained increases in plasma levels of several hormones including  hormone and IG F-1, but without affecting cortisol levels. It is currently under development as a potential treatment for reduced levels of these hormones, such as in  hormone deficient children or elderly adults, and human studies have shown it to increase both muscle mass and bone mineral density, making it a promising therapy for the treatment of frailty in the elderly. It also alters metabolism of body fat and so may have application in the treatment of obesity.